0001127602-20-025120.txt : 20200915
0001127602-20-025120.hdr.sgml : 20200915
20200915170004
ACCESSION NUMBER: 0001127602-20-025120
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200914
FILED AS OF DATE: 20200915
DATE AS OF CHANGE: 20200915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zaks Tal Zvi
CENTRAL INDEX KEY: 0001690927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 201176572
MAIL ADDRESS:
STREET 1: 122 BELLEVUE STREET
CITY: NEWTON
STATE: MA
ZIP: 02458
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-09-14
0001682852
Moderna, Inc.
MRNA
0001690927
Zaks Tal Zvi
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
Chief Medical Officer
Common Stock
2020-09-14
4
M
0
10000
20.93
A
10000
D
Common Stock
2020-09-14
4
M
0
34
14.22
A
10034
D
Common Stock
2020-09-14
4
M
0
10000
19.15
A
20034
D
Common Stock
2020-09-14
4
S
0
2082
60.86
D
17952
D
Common Stock
2020-09-14
4
S
0
2574
61.85
D
15378
D
Common Stock
2020-09-14
4
S
0
10210
62.79
D
5168
D
Common Stock
2020-09-14
4
S
0
5168
63.53
D
0
D
Stock Option (Right to Buy)
20.93
2020-09-14
4
M
0
10000
0
D
2020-03-08
2029-03-08
Common Stock
10000
229195
D
Stock Option (Right to Buy)
14.22
2020-09-14
4
M
0
34
0
D
2028-02-28
Common Stock
34
60209
D
Stock Option (Right to Buy)
19.15
2020-09-14
4
M
0
10000
0
D
2026-08-10
Common Stock
10000
134790
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.15 to $61.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.23 to $62.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.24 to $63.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.25 to $63.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.
This option is fully vested and exercisable.
/s/ Lori Henderson, as Attorney-in-Fact
2020-09-15